Skip to main content
Equibles
NKTR logo

NKTR · Nektar Therapeutics · Earnings Call Transcripts & Audio

Track NKTR — free

Use NKTR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NKTR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$60.55 +1.31 (+2.20%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$1.95B
Shares
34.14M
Volume · Sep 30 1.21M Avg daily vol (3M) 928.13K

Nektar Therapeutics Earnings Call Transcripts

Quarterly earnings calls for Nektar Therapeutics (NKTR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼5.2% $23.62M −$59.05M '22 Q3 22-11-03 ▼11.9% $22.02M −$59.69M '22 Q4 23-01-09 ▼13% $21.59M −$137.02M '23 Q1 23-04-17 ▼5% $20.50M −$51.12M '23 Q2 23-08-08 ▲2.2% $24.14M −$45.84M '23 Q3 23-11-07 ▲8.5% $23.89M −$42.08M '23 Q4 24-03-04 ▲0.2% $21.64M −$36.80M '24 Q1 24-05-09 ▲14.6% $23.49M −$52.36M '24 Q2 24-08-08 ▼0.1% $24.12M −$37.06M '24 Q3 24-11-07 ▲22.1% $29.18M $7.26M '24 Q4 25-03-12 ▼51.7% $10.46M −$50.88M '25 Q1 25-05-08 ▼52.4% $11.18M −$41.59M '25 Q2 25-08-07 ▼51.1% $11.79M −$35.52M '25 Q3 25-11-06 ▼25.3% $21.81M −$36.08M '25 Q4 26-03-12 ▲3.8% $10.86M −$44.90M '26 Q1 26-05-07 LATEST ▼9.3% $10.13M −$40.62M '26 Q2 26-08-13
Investor Update
Investor event
2026-10-01
Nektar Therapeutics (NKTR) October 2026 Investor Update
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Confident tone Market research and first-line positioning for ResPeg Atopic dermatitis dosing durability Alopecia areata Phase 3 / long-term extension
Revenue
$10.13M
▼ 9.3% YoY
Diluted EPS
$-1.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Nektar Therapeutics (NKTR) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Confident tone Atopic dermatitis (ectopic dermatitis) program Alopecia areata program Regulatory risk on moderate-population expansion
Revenue
$10.86M
▲ 3.8% YoY
Diluted EPS
$-1.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Confident tone Rezpeg/Respag in atopic dermatitis Balance sheet and financing Phase 3 readiness and regulatory alignment
Revenue
$21.81M*
▼ 25.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis (RESOLVE-AD) Alopecia areata Phase IIb (RESOLVE-AA) Type 1 diabetes / TrialNet partnership
Revenue
$11.79M
▼ 51.1% YoY
Diluted EPS
$-1.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Confident tone REZPEG/rezpegaldesleukin lead program Atopic dermatitis Phase IIb REZOLVE-AD results FDA Fast Track and Phase III planning
Revenue
$11.18M
▼ 52.4% YoY
Diluted EPS
$-2.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Positive tone REZPEG in atopic dermatitis (REZOLVE-AD) Early-stage pipeline (TNFR2 agonist) REZPEG in alopecia areata
Revenue
$10.46M
▼ 51.7% YoY
Diluted EPS
$-3.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call
Revenue
$29.18M*
▲ 22.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis REZPEG in alopecia areata NKTR-255 oncology program
Revenue
$24.12M
▼ 0.1% YoY
Diluted EPS
$-2.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call
Revenue
$23.49M
▲ 14.6% YoY
Diluted EPS
$-3.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Nektar Therapeutics (NKTR) Q1 2024 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis REZPEG in alopecia areata NKTR-0165 TNFR2 agonist
Revenue
$21.64M
▲ 0.2% YoY
Diluted EPS
$-2.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-04
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis TNFR2 / NKTR-0165 program REZPEG in alopecia areata
Revenue
$23.89M*
▲ 8.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
Revenue
$24.14M
▲ 2.2% YoY
Diluted EPS
$-3.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
Revenue
$20.50M
▼ 5% YoY
Diluted EPS
$-4.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-17
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Revenue
$21.59M
▼ 13% YoY
Diluted EPS
$-10.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Nektar Therapeutics (NKTR) Q4 2022 Earnings Call
Revenue
$22.02M*
▼ 11.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Nektar Therapeutics (NKTR) Q3 2022 Earnings Call Transcript
Revenue
$23.62M
▼ 5.2% YoY
Diluted EPS
$-4.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Nektar Therapeutics (NKTR) Q2 2022 Earnings Call Transcript
Revenue
$21.59M
▼ 23.8% YoY
Diluted EPS
$-12.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Nektar Therapeutics (NKTR) Q1 2022 Earnings Call
Revenue
$24.82M
▲ 5% YoY
Diluted EPS
$-7.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Nektar Therapeutics (NKTR) Q4 2021 Earnings Call Transcript
Revenue
$25.01M
▲ 6.6% YoY
Diluted EPS
$-11850.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript
Revenue
$24.92M
▼ 17% YoY
Diluted EPS
$-10.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript
Revenue
$28.33M
▼ 42% YoY
Diluted EPS
$-10.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript
Revenue
$23.65M
▼ 53.2% YoY
Diluted EPS
$-10.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript
Revenue
$23.46M
▼ 30.7% YoY
Diluted EPS
$-9.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Nektar Therapeutics (NKTR) Q3 2020 Earnings Call Transcript
Revenue
$30.03M
▲ 2.8% YoY
Diluted EPS
$-9.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Nektar Therapeutics (NKTR) Q2 2020 Earnings Call Transcript
Revenue
$48.85M
▲ 109.5% YoY
Diluted EPS
$-6.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
Revenue
$50.57M
▲ 79.2% YoY
Diluted EPS
$-11.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Nektar Therapeutics (NKTR) Q4 2019 Earnings Call
Revenue
$33.86M
▼ 15% YoY
Diluted EPS
$-9.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 906709 CUSIP 640268306 13F (30d) 7 filings 7 filers Visit website Investor relations